메뉴 건너뛰기




Volumn 67, Issue 2, 2012, Pages 245-256

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Author keywords

clinical trials; etanercept; long term treatment; psoriasis; safety

Indexed keywords

ETANERCEPT;

EID: 84863984952     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.07.040     Document Type: Article
Times cited : (68)

References (48)
  • 1
    • 3042845754 scopus 로고    scopus 로고
    • Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
    • DOI 10.1172/JCI200422147
    • B.J. Nickoloff, and F.O. Nestle Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities J Clin Invest 113 2004 1664 1675 (Pubitemid 39071656)
    • (2004) Journal of Clinical Investigation , vol.113 , Issue.12 , pp. 1664-1675
    • Nickoloff, B.J.1    Nestle, F.O.2
  • 3
    • 6344289544 scopus 로고    scopus 로고
    • Etanercept for the treatment of psoriasis and psoriatic arthritis
    • DOI 10.1111/j.1396-0296.2004.04043.x
    • A.B. Gottlieb Etanercept for the treatment of psoriasis and psoriatic arthritis Dermatol Ther 17 2004 401 408 (Pubitemid 39390594)
    • (2004) Dermatologic Therapy , vol.17 , Issue.5 , pp. 401-408
    • Gottlieb, A.B.1
  • 4
    • 32244438261 scopus 로고    scopus 로고
    • Fulfilling an unmet need in psoriasis: Do biologicals hold the key to improved tolerability?
    • DOI 10.2165/00002018-200629010-00004
    • N.H. Shear Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? Drug Saf 29 2006 49 66 (Pubitemid 43213895)
    • (2006) Drug Safety , vol.29 , Issue.1 , pp. 49-66
    • Shear, N.H.1
  • 6
    • 0242660438 scopus 로고    scopus 로고
    • Lymphoma Rates Are Low but Increased in Patients with Psoriasis: Results from a Population-Based Cohort Study in the United Kingdom
    • DOI 10.1001/archderm.139.11.1425
    • J.M. Gelfand, J. Berlin, A. Van Voorhees, and D.J. Margolis Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom Arch Dermatol 139 2003 1425 1429 (Pubitemid 37433132)
    • (2003) Archives of Dermatology , vol.139 , Issue.11 , pp. 1425-1429
    • Gelfand, J.M.1    Berlin, J.2    Van Voorhees, A.3    Margolis, D.J.4
  • 12
  • 13
    • 27144456788 scopus 로고    scopus 로고
    • Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial
    • DOI 10.1016/j.jaad.2005.06.053, PII S0190962205023017
    • S.R. Feldman, A.B. Kimball, G.G. Krueger, J.M. Woolley, D. Lalla, and A. Jahreis Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial J Am Acad Dermatol 53 2005 887 889 (Pubitemid 41501389)
    • (2005) Journal of the American Academy of Dermatology , vol.53 , Issue.5 , pp. 887-889
    • Feldman, S.R.1    Kimball, A.B.2    Krueger, G.G.3    Woolley, J.M.4    Lalla, D.5    Jahreis, A.6
  • 16
    • 44049097512 scopus 로고    scopus 로고
    • Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: Continuous versus interrupted treatment
    • DOI 10.1111/j.1524-4733.2007.00251.x
    • J.M. Gelfand, A.B. Kimball, E.N. Mostow, C.F. Chiou, V. Patel, and H.A. Xia Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment Value Health 11 2008 400 407 (Pubitemid 351712967)
    • (2008) Value in Health , vol.11 , Issue.3 , pp. 400-407
    • Gelfand, J.M.1    Kimball, A.B.2    Mostow, E.N.3    Chiou, C.-F.4    Patel, V.5    Xia, H.A.6    Freundlich, B.7    Stevens, S.R.8
  • 17
    • 54249097066 scopus 로고    scopus 로고
    • Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: A randomized controlled trial with open-label extension
    • P.C. van de Kerkhof, S. Segaert, M. Lahfa, T.A. Luger, Z. Karolyi, and A. Kaszuba Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension Br J Dermatol 159 2008 1177 1185
    • (2008) Br J Dermatol , vol.159 , pp. 1177-1185
    • Van De Kerkhof, P.C.1    Segaert, S.2    Lahfa, M.3    Luger, T.A.4    Karolyi, Z.5    Kaszuba, A.6
  • 18
    • 32644448881 scopus 로고    scopus 로고
    • Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial
    • G.G. Krueger, B. Elewski, K. Papp, A. Wang, R. Zitnik, and A. Jahreis Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial J Am Acad Dermatol 54 Suppl 2006 S112 S119
    • (2006) J Am Acad Dermatol , vol.54 , Issue.SUPPL.
    • Krueger, G.G.1    Elewski, B.2    Papp, K.3    Wang, A.4    Zitnik, R.5    Jahreis, A.6
  • 20
    • 33646464514 scopus 로고    scopus 로고
    • Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience
    • L.W. Moreland, M.E. Weinblatt, E.C. Keystone, J.M. Kremer, R.W. Martin, and M.H. Schiff Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience J Rheumatol 33 2006 854 861
    • (2006) J Rheumatol , vol.33 , pp. 854-861
    • Moreland, L.W.1    Weinblatt, M.E.2    Keystone, E.C.3    Kremer, J.M.4    Martin, R.W.5    Schiff, M.H.6
  • 21
    • 33751268255 scopus 로고    scopus 로고
    • A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs
    • DOI 10.1136/ard.2005.038349
    • L. Klareskog, M. Gaubitz, V. Rodriguez-Valverde, M. Malaise, M. Dougados, and J. Wajdula A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs Ann Rheum Dis 65 2006 1578 1584 (Pubitemid 44799668)
    • (2006) Annals of the Rheumatic Diseases , vol.65 , Issue.12 , pp. 1578-1584
    • Klareskog, L.1    Gaubitz, M.2    Rodriguez-Valverde, V.3    Malaise, M.4    Dougados, M.5    Wajdula, J.6
  • 22
    • 67549117204 scopus 로고    scopus 로고
    • The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events
    • J.P. Leombruno, T.R. Einarson, and E.C. Keystone The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events Ann Rheum Dis 68 2009 1136 1145
    • (2009) Ann Rheum Dis , vol.68 , pp. 1136-1145
    • Leombruno, J.P.1    Einarson, T.R.2    Keystone, E.C.3
  • 23
    • 79952610089 scopus 로고    scopus 로고
    • Enbrel [etanercept] Immunex Corp, marketed by Amgen and Wyeth Pharmaceuticals Thousand Oaks (CA)
    • Enbrel [etanercept] Full Prescribing Information 2010 Immunex Corp, marketed by Amgen and Wyeth Pharmaceuticals Thousand Oaks (CA)
    • (2010) Full Prescribing Information
  • 24
    • 34250761386 scopus 로고    scopus 로고
    • Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
    • DOI 10.1001/archderm.143.6.719
    • S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, and M. Dunn Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 2007 719 726 (Pubitemid 46955730)
    • (2007) Archives of Dermatology , vol.143 , Issue.6 , pp. 719-726
    • Tyring, S.1    Gordon, K.B.2    Poulin, Y.3    Langley, R.G.4    Gottlieb, A.B.5    Dunn, M.6    Jahreis, A.7
  • 27
    • 84873612401 scopus 로고    scopus 로고
    • Amgen Inc [ identifier NCT00121615 ] Available from Accessed April 25 2011
    • Amgen Inc. Study of etanercept in the treatment of psoriasis in adult subjects [ ClinicalTrials.gov identifier NCT00121615 ]. Available from: http://clinicaltrials.gov/ct2/show/NCT00121615?term= etanercept+and+psoriasis&rank=39. Accessed April 25, 2011.
    • Study of Etanercept in the Treatment of Psoriasis in Adult Subjects
  • 28
    • 84873609770 scopus 로고    scopus 로고
    • National Cancer Institute Available from:. Accessed April 12 2011
    • National Cancer Institute. Common toxicity criteria, version 2.0. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcv20-4-30-992.pdf. Accessed April 12, 2011.
    • Common Toxicity Criteria, Version 2.0.
  • 29
    • 0348243012 scopus 로고    scopus 로고
    • Maintenance and support services organization. Available from:. Accessed April 25 2011
    • Medical Dictionary for Regulatory Activities (MedDRA) Version 7.0. Maintenance and support services organization. Available from: http://www.meddramsso.com/. Accessed April 25, 2011.
    • Medical Dictionary for Regulatory Activities (MedDRA) Version 7.0
  • 31
    • 84873610078 scopus 로고    scopus 로고
    • National Cancer Institute November 2005 submission (1992-2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission. Available from:. Accessed April 25 2011
    • National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program SEERStat database: incidence-SEER 13 Regs public-use, November 2005 submission (1992-2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission. Available from: http://www.seer.cancer.gov/. Accessed April 25, 2011.
    • Surveillance, Epidemiology, and End Results (SEER) Program SEERStat Database: Incidence-SEER 13 Regs Public-use
  • 32
    • 0030912824 scopus 로고    scopus 로고
    • Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992
    • D.T. Gray, V.J. Suman, W.P. Su, R.P. Clay, W.S. Harmsen, and R.K. Roenigk Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992 Arch Dermatol 133 1997 735 740 (Pubitemid 27263707)
    • (1997) Archives of Dermatology , vol.133 , Issue.6 , pp. 735-740
    • Gray, D.T.1    Suman, V.J.2    Daniel Su, W.P.3    Clay, R.P.4    Harmsen, W.S.5    Roenigk, R.K.6
  • 33
    • 0034816721 scopus 로고    scopus 로고
    • Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996
    • DOI 10.1067/mjd.2001.114742
    • R.B. Harris, K. Griffith, and T.E. Moon Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996 J Am Acad Dermatol 45 2001 528 536 (Pubitemid 32917246)
    • (2001) Journal of the American Academy of Dermatology , vol.45 , Issue.4 , pp. 528-536
    • Harris, R.B.1    Griffith, K.2    Moon, T.E.3
  • 34
    • 32644437923 scopus 로고    scopus 로고
    • Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database
    • A.B. Gottlieb, C.L. Leonardi, B.S. Goffe, J.-P. Ortonne, P. van der Kerkhof, and R. Zitnick Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database J Am Acad Dermatol 54 Suppl 2006 S92 S100
    • (2006) J Am Acad Dermatol , vol.54 , Issue.SUPPL.
    • Gottlieb, A.B.1    Leonardi, C.L.2    Goffe, B.S.3    Ortonne, J.-P.4    Van Der Kerkhof, P.5    Zitnick, R.6
  • 35
    • 80052991902 scopus 로고    scopus 로고
    • Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications
    • A.B. Gottlieb, K. Gordon, E.H. Giannini, P. Mease, J. Li, and Y. Chon Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications J Drugs Dermatol 10 2011 289 300
    • (2011) J Drugs Dermatol , vol.10 , pp. 289-300
    • Gottlieb, A.B.1    Gordon, K.2    Giannini, E.H.3    Mease, P.4    Li, J.5    Chon, Y.6
  • 37
    • 24944529247 scopus 로고    scopus 로고
    • TNF-blocking agents and tuberculosis: New drugs illuminate an old topic
    • DOI 10.1093/rheumatology/keh567
    • J. Keane TNF-blocking agents and tuberculosis: new drugs illuminate an old topic Rheumatology (Oxford) 44 2005 714 720 (Pubitemid 41487198)
    • (2005) Rheumatology , vol.44 , Issue.6 , pp. 714-720
    • Keane, J.1
  • 40
    • 0035678652 scopus 로고    scopus 로고
    • Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden
    • DOI 10.1046/j.0022-202x.2001.01520.x
    • P. Boffetta, G. Gridley, and B. Lindelof Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden J Invest Dermatol 117 2001 1531 1537 (Pubitemid 34032784)
    • (2001) Journal of Investigative Dermatology , vol.117 , Issue.6 , pp. 1531-1537
    • Boffetta, P.1    Gridley, G.2    Lindelof, B.3
  • 42
    • 15044361996 scopus 로고    scopus 로고
    • High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients
    • DOI 10.1111/j.0022-202X.2005.23618.x
    • J.L. Lim, and R.S. Stern High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients J Invest Dermatol 124 2005 505 513 (Pubitemid 40381572)
    • (2005) Journal of Investigative Dermatology , vol.124 , Issue.3 , pp. 505-513
    • Lim, J.L.1    Stern, R.S.2
  • 43
    • 19444375889 scopus 로고    scopus 로고
    • Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use
    • S.M. Behnam, S.E. Behnam, and J.Y. Koo Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use J Drugs Dermatol 4 2005 189 194
    • (2005) J Drugs Dermatol , vol.4 , pp. 189-194
    • Behnam, S.M.1    Behnam, S.E.2    Koo, J.Y.3
  • 46
    • 34848893989 scopus 로고    scopus 로고
    • Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study
    • DOI 10.1002/art.22864
    • F. Wolfe, and K. Michaud Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study Arthritis Rheum 56 2007 2886 2895 (Pubitemid 47502734)
    • (2007) Arthritis and Rheumatism , vol.56 , Issue.9 , pp. 2886-2895
    • Wolfe, F.1    Michaud, K.2
  • 48
    • 33644875213 scopus 로고    scopus 로고
    • TNF-alpha inhibitors and congestive heart failure
    • S.M. Behnam, S.E. Behnam, and J.Y. Koo TNF-alpha inhibitors and congestive heart failure Skinmed 4 2005 363 368
    • (2005) Skinmed , vol.4 , pp. 363-368
    • Behnam, S.M.1    Behnam, S.E.2    Koo, J.Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.